Join
Live feed
·
PRReleasevia Quantisnow
ImmunityBio Inc. logo

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

ByQuantisnow·Wall Street's wire, on your screen.
IBRX· ImmunityBio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IBRX (ImmunityBio Inc.) and more on Quantisnow.